The short version of GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-21 and is reviewed periodically as new material appears.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The first observation of electrophoresis occurred during first years of 19th century independently by Gautherot in 1801 and by Reuss in 1809. The history of electrokinetics and electrophoresis for their most widely used applications, such as molecular separation and chemical analysis, began with the work of Arne Tiselius in 1931, while new separation processes and chemical speciation analysis techniques based on electrophoresis and electrokinetics continue to be developed in the 21st century. Tiselius, with support from the Rockefeller Foundation, developed the moving-boundary electrophoresis, which was described in 1937 in his well-known paper. The method spread slowly until the advent of effective zone electrophoresis methods in the 1940s and 1950s, which used filter paper or gels as supporting media. By the 1960s, increasingly sophisticated gel electrophoresis methods made it possible to separate biological molecules based on minute physical and chemical differences, helping to drive the rise of molecular biology and biochemistry. Gel electrophoresis and related techniques became the basis for a wide range of biochemical methods, such as protein fingerprinting, Southern blot, other blotting procedures, DNA sequencing, and many more.
=== Contestants === 1st - Melanie Bjork-Jensen, Self-taught baker from West Jordan, Utah 2nd/3rd/4th - Alan Arras, Pastry Sous Chef from Orlando, Florida 2nd/3rd/4th - Cory Jones, Bakery Owner from Unadilla, Georgia 2nd/3rd/4th - Oksana Shchelgachova, Pastry Chef and Owner of Pastry Boutique from Highlands, North Carolina 5th - Camille La Caer, Pastry Chef from Buffalo, New York 6th - Jake Hagen, Pastry Chef from Granada Hills, California 7/8th - Gonzuela Bastarache, Home Baker from Moncton, New Brunswick, Canada 7/8th - Megan Carroll, Food Photographer from Minneapolis, Minnesota 9th - Nina Charles, Cake Artist and Bakery Owner from Carencro, Louisiana 10th - Justin Giordano, Cake Artist from New York City, New York
== Pathophysiology == When small crystalline silica dust particles are inhaled, they can embed themselves deeply into the tiny alveolar sacs and ducts in the lungs, where oxygen and carbon dioxide gases are exchanged. There, the lungs cannot clear out the dust by mucus or coughing. When fine particles of crystalline silica dust are deposited in the lungs, macrophages that ingest the dust particles will set off an inflammatory response by releasing tumor necrosis factors, interleukin-1, leukotriene B4 and other cytokines. In turn, these stimulate fibroblasts to proliferate and produce collagen around the silica particle, thus resulting in fibrosis and the formation of the nodular lesions. The inflammatory effects of crystalline silica are apparently mediated by the NLRP3 inflammasome. Characteristic lung tissue pathology in nodular silicosis consists of fibrotic nodules with concentric "onion-skinned" arrangement of collagen fibers, central hyalinization, and a cellular peripheral zone, with lightly birefringent particles seen under polarized light. The silicotic nodule represents a specific tissue response to crystalline silica. In acute silicosis, microscopic pathology shows a periodic acid-Schiff positive alveolar exudate (alveolar lipoproteinosis) and a cellular infiltrate of the alveolar walls.
tried to fight with Noriega's help, remained firmly in power in Nicaragua, and argued that this demonstrated the failure of the U.S.'s approach to Latin American interventions. Noriega took great care to shape perceptions of him. He permitted and encouraged rumors that as Panama's chief of intelligence, he was in possession of negative information about everybody in the country. Dinges suggests that the impression among some officials that Noriega made money off of every transaction in the country may have been cultivated by Noriega himself. Among opposition leaders in Panama, he was seen variously as a sexual pervert, a sadist, and a rapist. Within U.S. government circles, contradictory images abounded; Noriega was seen as a CIA spy, a drug trafficker, a nationalist supporting Torrijos, an ally of Cuba, and an ally of Oliver North and the Contras. He was perceived as a trusted collaborator in the war against drugs, even as the DEA was investigating him for involvement in smuggling. By the time of his removal, he had come to be hated in the U.S., and the invasion was portrayed as an attempt to remove an evil man. Dinges writes that these contradictory images played a large role in shaping the U.S. government's self-contradictory policy towards Noriega. Noriega used the moniker "El Man" to refer to himself, but he was also derogatorily known as cara de piña, or "pineapple face" in Spanish, as a result of pockmarked features left by acne in his youth. He detested the name, and it would later be the subject of a lawsuit.
Sources: en.wikipedia.org
=== Glucose tolerance === Middle aged (10‐month‐old) mice fed a high fat diet gained body weight and fat mass in the lower parts of their bodies and had impaired glucose tolerance as defined in glucose tolerance tests. Adding α-ketoglutarate to the drinking water of these mice inhibited the development of these changes. These results suggest that drinking the α-ketoglutarate-rich water replenished the otherwise diminished supplies of α-ketoglutarate in middle aged mice; the replenished supply of α-ketoglutarate thereby became available to suppress obesity and improve glucose tolerance. A study in rats feed a low fat or high fat diet for 27 weeks and drinking α-ketoglutarate-rich water for the last 12 weeks of this 27 week period decreased their fat issue masses and increased their whole-body insulin sensitivity as defined in glucose tolerance tests. Rats fed either of these diets but not given α-ketoglutarate-rich water did not show these changes. This study indicates that α-ketoglutarate regulates body fat mass and insulin sensitivity in rats as well as mice.
In 1993, the church was held liable for the first time (overturned on appeal), after 11-year-old Ian Lundman died of hyperglycemia in Minnesota in 1989. The church sent a Christian Science nurse to sit with him; doctors testified that he could have been saved by an insulin injection up to two hours before his death. The mother and stepfather were charged with manslaughter, but the charges were dismissed. The boy's father, Douglass Lundman, sued the mother, stepfather, practitioner, nurse, nursing home and church. He was awarded $5.2 million compensatory damages, later reduced to $1.5 million, and $9 million in punitive damages against the church. The Minnesota State Court of Appeals overturned the award against the church and nursing home in 1995, finding that a judgment that forced the church to "abandon teaching its central tenet" was unconstitutional, and that while the individuals had a duty of care toward the boy, the church and nursing home did not.
Infected dogs carry the highest bacterial load of B. canis after 1-6 months after infection. Infected neutered animals are not able to display reproductive symptoms, however both intact and neutered dogs are able to shed B. canis in urine. This means that both neutered and intact dogs are able to transmit the disease via urine. B. canis is found to be localized in the prostate of male dogs, thus transmitting through the urine in both intact and neutered males. It has been suggested that male dogs carry higher concentrations of the bacteria when compared to female dogs due contamination from seminal fluid. Neutered dogs are also capable of shedding the bacteria in their saliva and nasal secretions. B. canis is the least common cause of Brucellosis in humans. Transmission to humans is rarely diagnosed but is possible. It can be transmitted via bodily fluids and aborted material. Signs and symptoms are very non-specific, such as fever, joint pain, and fatigue. The disease can also be debilitating, causing conditions such as endocarditis, splenomegaly, or neurologic symptoms.
==== Companion of the Order of St Michael and St George (CMG) ==== Roger George Bowers, , Assistant Director General, The British Council. Lieutenant General Sir Michael John Dawson Walker, (481887), late The Royal Anglian Regiment. Diplomatic Service and Overseas List Major General Patrick Guy Brooking, . For services to UK-German relations in Berlin. Anthony Joyce Cary, Counsellor, Foreign and Commonwealth Office. John-Donovan Nelson dalla Rosa Clibborn, Counsellor, Foreign and Commonwealth Office. Antony Ford, lately Counsellor, Foreign and Commonwealth Office. Maureen Elizabeth MacGlashan, HM Ambassador, Holy See. David Trulock Ricks, . lately Director, British Council, France. Hilary Nicholas Hugh Synnott, lately Minister, British High Commission, New Delhi.
Bovine somatotropin or bovine somatotrophin (abbreviated bST and BST), or bovine growth hormone (BGH), is a peptide hormone produced by cows' pituitary glands. Like other hormones, it is produced in small quantities and is used in regulating metabolic processes. Recombinant bovine somatotropin (usually "rBST") is a synthetic version of the bovine growth hormone given to dairy cattle by injection to increase milk production. BST increases milk production by around 10 percent. Controversy over its safety for cows has led to rBST being banned in several countries, including the European Union since 1990, and Canada, Japan, Pakistan, Australia, New Zealand, and Argentina, as it has been found to increase health risks in cows. The Codex Alimentarius has not approved it as safe. The FDA approved it in 1993 and gave guidance to manufacturers that marking a product as "bST-free" or "rbST free" is misleading and a less misleading text would be "No significant difference has been shown between milk derived from rbST-treated and non-rbST-treated cows".
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.